Share Name Share Symbol Market Type Share ISIN Share Description
Hvivo Plc LSE:HVO London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.25 5.81% 22.75 22.50 23.00 22.75 20.75 21.375 2,052,409 10:19:15
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 11.0 -18.9 -21.3 - 19

Open Orphan PLC Capital Markets Day

20/10/2022 7:00am

UK Regulatory (RNS & others)

Hvivo (LSE:HVO)
Historical Stock Chart

From Aug 2022 to Feb 2023

Click Here for more Hvivo Charts.


RNS Number : 4809D

Open Orphan PLC

20 October 2022

Open Orphan plc

("Open Orphan" or the "Company")

Capital Markets Day

Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces it will be holding a Capital Markets Day for analysts, institutional investors and media on Wednesday 2 November 2022 at 9.30 am - 12.00 pm (GMT).

The event, which will be chaired by CEO Yamin 'Mo' Khan, will provide a deeper insight into the Company's end-to-end early clinical development services business, the human challenge trial market, and the benefits of human challenge to the Company's clients. There will also be an opportunity for attendees to take part in a Q&A with the Company's management team including its new CFO, Stephen Pinkerton, and guest speakers which include Peter Openshaw, Professor of Experimental Medicine at Imperial College London.

Analysts, institutional investors and media are welcome to attend the event in the City of London. Due to restrictions on numbers, it will not be possible for all interested parties to attend in-person, however, a live webcast will be available on the Company's website for retail investors and others to view the presentations here .

To register your interest for the webcast, please contact Walbrook PR on +44 20 7933 8780 or email .

A recording of the presentation will be made available on the Company's website after the event.

For further information please contact:

 Open Orphan plc                                                        +44 (0) 20 7756 1300 
 Yamin 'Mo' Khan, Chief Executive 
 Liberum Capital (Nominated Adviser 
  and Joint Broker)                                                     +44 (0) 20 3100 2000 
 Ben Cryer/ Edward Mansfield/ Phil 
  Walker/ Will King 
 finnCap plc (Joint Broker)                                             +44 (0) 20 7220 0500 
 Geoff Nash / James Thompson / Richard 
 Davy (Euronext Growth Adviser and 
  Joint Broker)                                                          +353 (0) 1 679 6363 
 Anthony Farrell 
 Walbrook PR (Financial PR & IR)           +44 (0) 20 7933 8780 or 
  Stephanie Cuthbert / Phillip                       +44 (0) 7796 794 663 / +44 (0) 7867 984 
  Marriage /                                                                           082 / 
  Louis Ashe-Jepson                                                     +44 (0) 7747 515 393 

Notes to Editors

Open Orphan plc (Ticker: ORPH) is changing its name to hVIVO plc (Ticker: HVO), which is expected to take effect on the AIM market of the London Stock Exchange and the Euronext Growth Exchange market on 26 October 2022.

Open Orphan is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

October 20, 2022 02:00 ET (06:00 GMT)

1 Year Hvivo Chart

1 Year Hvivo Chart

1 Month Hvivo Chart

1 Month Hvivo Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20230209 10:37:30